PolyPid shareholders approve Proposal 1 at EGM

PolyPid Ltd. held an Extraordinary General Meeting of Shareholders on February 4, 2026, where a quorum was present and shareholders approved Proposal No. 1 as originally proposed.

Rhea-AI Filing Summary

PolyPid Ltd. held an Extraordinary General Meeting of Shareholders on February 4, 2026, where a quorum was present and shareholders approved Proposal No. 1 as originally proposed. The specific substance of the proposal is not described in this excerpt.

The report states that this 6-K is incorporated by reference into several existing Form F-3 and Form S-8 registration statements, meaning those securities registration documents now also include this shareholder meeting outcome as part of their disclosure record.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PolyPid Ltd. (PYPD) announce in its February 2026 Form 6-K?

PolyPid Ltd. reported that it held an Extraordinary General Meeting of Shareholders on February 4, 2026, where a quorum was present and shareholders approved Proposal No. 1 as originally proposed. The filing also links this outcome into several existing F-3 and S-8 registration statements.

What was decided at PolyPid Ltd.’s Extraordinary General Meeting on February 4, 2026?

At the February 4, 2026 Extraordinary General Meeting, PolyPid Ltd. shareholders approved Proposal No. 1 as originally proposed, with a quorum present. The filing does not describe the content of the proposal but confirms that the approval is now part of the company’s incorporated SEC disclosures.

How does this PolyPid Ltd. (PYPD) 6-K affect its existing F-3 and S-8 registrations?

The 6-K states it is incorporated by reference into PolyPid’s Form F-3 and Form S-8 registration statements, making the shareholder meeting and Proposal No. 1 approval part of those filings. This updates the disclosure package for any securities registered under those forms going forward.

When and where was PolyPid Ltd.’s Extraordinary General Meeting held?

PolyPid Ltd. convened its Extraordinary General Meeting of Shareholders on February 4, 2026. The company’s principal executive office is listed as 18 Hasivim Street, Petach Tikva, Israel, and the meeting outcome is summarized in this Form 6-K report filed under the Securities Exchange Act.

Who signed PolyPid Ltd.’s February 2026 Form 6-K?

The Form 6-K was signed on behalf of PolyPid Ltd. by Dikla Czaczkes Akselbrad, identified as the company’s Chief Executive Officer. The signature section confirms that the registrant caused the report to be signed under the requirements of the Securities Exchange Act of 1934.

What SEC reporting framework does PolyPid Ltd. use for its annual reports?

PolyPid Ltd. indicates it files its annual reports under cover of Form 20-F, the standard annual report form for foreign private issuers. This is noted in the 6-K alongside other basic company information such as the Commission File Number and principal executive office address.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 04:05 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of: February 2026

Commission File Number: 001-38428

PolyPid Ltd.

(Translation of registrant’s name into English)

18 Hasivim Street

Petach Tikva 495376, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F      ☐ Form 40-F

CONTENTS

Meeting of Shareholders

On February 4, 2026, PolyPid Ltd. (the “Company”) convened an Extraordinary General Meeting of Shareholders (the “Meeting”). The Meeting was called for the following purpose:

Proposal No. 1 To approve the compensation terms of Ms. Brooke Story, the chairman of the Company’s board of directors.

At the Meeting, a quorum was present and the shareholders of the Company approved Proposal No. 1 as originally proposed.

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s registration statements on Form F-3 (File No. 333-276826, File No. 333-280658, File No. 333-281863, File No. 333-284376 and File No. 333-289034)  and Form S-8 (File No. 333-239517, File No. 333-271060, File No. 333-277703, File No. 333-280662 and File No. 333-289570) filed with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	POLYPID LTD.
Date: February 4, 2026	By:	/s/ Dikla Czaczkes Akselbrad
		Name	Dikla Czaczkes Akselbrad
		Title:	Chief Executive Officer

2